| molecular function |
|---|
| | GO:0004000 | | adenosine deaminase activity | | Catalysis of the reaction: adenosine + H2O = inosine + NH3. |
| | GO:0019239 | | deaminase activity | | Catalysis of the removal of an amino group from a substrate, producing ammonia (NH3). |
| | GO:0016787 | | hydrolase activity | | Catalysis of the hydrolysis of various bonds, e.g. C-O, C-N, C-C, phosphoric anhydride bonds, etc. Hydrolase is the systematic name for any enzyme of EC class 3. |
| | GO:0046872 | | metal ion binding | | Interacting selectively and non-covalently with any metal ion. |
| | GO:0001883 | | purine nucleoside binding | | Interacting selectively and non-covalently with a purine nucleoside, a compound consisting of a purine base linked either to ribose or deoxyribose. |
| | GO:0008270 | | zinc ion binding | | Interacting selectively and non-covalently with zinc (Zn) ions. |
| biological process |
|---|
| | GO:0048541 | | Peyer's patch development | | The process whose specific outcome is the progression of Peyer's patches over time, from their formation to the mature structure. Peyer's patches are typically found as nodules associated with gut epithelium with distinct internal structures including B- and T-zones for the activation of lymphocytes. |
| | GO:0042110 | | T cell activation | | The change in morphology and behavior of a mature or immature T cell resulting from exposure to a mitogen, cytokine, chemokine, cellular ligand, or an antigen for which it is specific. |
| | GO:0006154 | | adenosine catabolic process | | The chemical reactions and pathways resulting in the breakdown of adenosine, adenine riboside, a ribonucleoside found widely distributed in cells of every type as the free nucleoside and in combination in nucleic acids and various nucleoside coenzymes. |
| | GO:0046085 | | adenosine metabolic process | | The chemical reactions and pathways involving adenosine, adenine riboside, a ribonucleoside found widely distributed in cells of every type as the free nucleoside and in combination in nucleic acids and various nucleoside coenzymes. |
| | GO:0007568 | | aging | | A developmental process that is a deterioration and loss of function over time. Aging includes loss of functions such as resistance to disease, homeostasis, and fertility, as well as wear and tear. Aging includes cellular senescence, but is more inclusive. May precede death and may succeed developmental maturation (GO:0021700). |
| | GO:0007155 | | cell adhesion | | The attachment of a cell, either to another cell or to an underlying substrate such as the extracellular matrix, via cell adhesion molecules. |
| | GO:0046061 | | dATP catabolic process | | The chemical reactions and pathways resulting in the breakdown of dATP, deoxyadenosine triphosphate (2'-deoxyadenosine 5'-triphosphate). |
| | GO:0006157 | | deoxyadenosine catabolic process | | The chemical reactions and pathways resulting in the breakdown of deoxyadenosine, 2-deoxyribosyladenine, one of the four major nucleosides of DNA. |
| | GO:0048566 | | embryonic digestive tract development | | The process whose specific outcome is the progression of the gut over time, from its formation to the mature structure during embryonic development. The gut is the region of the digestive tract extending from the beginning of the intestines to the anus. |
| | GO:0002314 | | germinal center B cell differentiation | | The process in which a B cell in the spleen acquires the specialized features of a germinal center B cell. Germinal center B cells are rapidly cycling B cells which have downregulated IgD expression and exhibit high levels of binding by peanut agglutinin (PNA). |
| | GO:0001821 | | histamine secretion | | The regulated release of histamine by a cell or tissue. It is formed by decarboxylation of histidine and it acts through receptors in smooth muscle and in secretory systems. |
| | GO:0046101 | | hypoxanthine biosynthetic process | | The chemical reactions and pathways resulting in the formation of hypoxanthine, 6-hydroxy purine, an intermediate in the degradation of adenylate. Its ribonucleoside is known as inosine and its ribonucleotide as inosinate. |
| | GO:0043103 | | hypoxanthine salvage | | Any process that generates hypoxanthine, 6-hydroxy purine, from derivatives of it without de novo synthesis. |
| | GO:0001701 | | in utero embryonic development | | The process whose specific outcome is the progression of the embryo in the uterus over time, from formation of the zygote in the oviduct, to birth. An example of this process is found in Mus musculus. |
| | GO:0046103 | | inosine biosynthetic process | | The chemical reactions and pathways resulting in the formation of inosine, hypoxanthine riboside, a nucleoside found free but not in combination in nucleic acids except in the anticodons of some tRNAs. |
| | GO:0001889 | | liver development | | The process whose specific outcome is the progression of the liver over time, from its formation to the mature structure. The liver is an exocrine gland which secretes bile and functions in metabolism of protein and carbohydrate and fat, synthesizes substances involved in the clotting of the blood, synthesizes vitamin A, detoxifies poisonous substances, stores glycogen, and breaks down worn-out erythrocytes. |
| | GO:0048286 | | lung alveolus development | | The process whose specific outcome is the progression of the alveolus over time, from its formation to the mature structure. The alveolus is a sac for holding air in the lungs; formed by the terminal dilation of air passageways. |
| | GO:0030324 | | lung development | | The process whose specific outcome is the progression of the lung over time, from its formation to the mature structure. In all air-breathing vertebrates the lungs are developed from the ventral wall of the oesophagus as a pouch which divides into two sacs. In amphibians and many reptiles the lungs retain very nearly this primitive sac-like character, but in the higher forms the connection with the esophagus becomes elongated into the windpipe and the inner walls of the sacs become more and more divided, until, in the mammals, the air spaces become minutely divided into tubes ending in small air cells, in the walls of which the blood circulates in a fine network of capillaries. In mammals the lungs are more or less divided into lobes, and each lung occupies a separate cavity in the thorax. |
| | GO:0060169 | | negative regulation of adenosine receptor signaling pathway | | Any process that stops, prevents, or reduces the frequency, rate or extent of the adenosine receptor signaling pathway. The adenosine receptor pathway is the series of molecular signals generated as a consequence of an adenosine receptor binding to one of its physiological ligands. |
| | GO:0043066 | | negative regulation of apoptotic process | | Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptotic process. |
| | GO:0042323 | | negative regulation of circadian sleep/wake cycle, non-REM sleep | | Any process that stops, prevents or reduces the duration or quality of non-rapid eye movement (NREM) sleep. |
| | GO:0050728 | | negative regulation of inflammatory response | | Any process that stops, prevents, or reduces the frequency, rate or extent of the inflammatory response. |
| | GO:0002686 | | negative regulation of leukocyte migration | | Any process that stops, prevents, or reduces the frequency, rate, or extent of leukocyte migration. |
| | GO:0002906 | | negative regulation of mature B cell apoptotic process | | Any process that stops, prevents, or reduces the frequency, rate, or extent of mature B cell apoptotic process. |
| | GO:0070256 | | negative regulation of mucus secretion | | Any process that stops, prevents, or reduces the frequency, rate or extent of the regulated release of mucus from a cell or a tissue. |
| | GO:0060407 | | negative regulation of penile erection | | Any process that stops, prevents, or reduces the rate, frequency or extent of penile erection. Penile erection is the hardening, enlarging and rising of the penis which often occurs in the sexually aroused male and enables sexual intercourse. Achieved by increased inflow of blood into the vessels of erectile tissue, and decreased outflow. |
| | GO:0070244 | | negative regulation of thymocyte apoptotic process | | Any process that stops, prevents, or reduces the frequency, rate or extent of thymocyte death by apoptotic process. |
| | GO:0009117 | | nucleotide metabolic process | | The chemical reactions and pathways involving a nucleotide, a nucleoside that is esterified with (ortho)phosphate or an oligophosphate at any hydroxyl group on the glycose moiety; may be mono-, di- or triphosphate; this definition includes cyclic nucleotides (nucleoside cyclic phosphates). |
| | GO:0001890 | | placenta development | | The process whose specific outcome is the progression of the placenta over time, from its formation to the mature structure. The placenta is an organ of metabolic interchange between fetus and mother, partly of embryonic origin and partly of maternal origin. |
| | GO:0030890 | | positive regulation of B cell proliferation | | Any process that activates or increases the rate or extent of B cell proliferation. |
| | GO:0050870 | | positive regulation of T cell activation | | Any process that activates or increases the frequency, rate or extent of T cell activation. |
| | GO:0045582 | | positive regulation of T cell differentiation | | Any process that activates or increases the frequency, rate or extent of T cell differentiation. |
| | GO:0033089 | | positive regulation of T cell differentiation in thymus | | Any process that activates or increases the frequency, rate or extent of T cell differentiation in the thymus. |
| | GO:0050862 | | positive regulation of T cell receptor signaling pathway | | Any process that activates or increases the frequency, rate or extent of signaling pathways initiated by the cross-linking of an antigen receptor on a T cell. |
| | GO:0046638 | | positive regulation of alpha-beta T cell differentiation | | Any process that activates or increases the frequency, rate or extent of alpha-beta T cell differentiation. |
| | GO:0050850 | | positive regulation of calcium-mediated signaling | | Any process that activates or increases the frequency, rate or extent of calcium-mediated signaling. |
| | GO:0002636 | | positive regulation of germinal center formation | | Any process that activates or increases the frequency, rate, or extent of germinal center formation. |
| | GO:0010460 | | positive regulation of heart rate | | Any process that activates or increases the frequency or rate of heart contraction. |
| | GO:0045987 | | positive regulation of smooth muscle contraction | | Any process that activates or increases the frequency, rate or extent of smooth muscle contraction. |
| | GO:0032261 | | purine nucleotide salvage | | Any process which produces a purine nucleotide from derivatives of it, without de novo synthesis. |
| | GO:0009168 | | purine ribonucleoside monophosphate biosynthetic process | | The chemical reactions and pathways resulting in the formation of purine ribonucleoside monophosphate, a compound consisting of a purine base linked to a ribose sugar esterified with phosphate on the sugar. |
| | GO:0045580 | | regulation of T cell differentiation | | Any process that modulates the frequency, rate or extent of T cell differentiation. |
| | GO:0033632 | | regulation of cell-cell adhesion mediated by integrin | | Any process that modulates the frequency, rate, or extent of cell-cell adhesion mediated by integrin. |
| | GO:0045187 | | regulation of circadian sleep/wake cycle, sleep | | Any process that modulates the frequency, rate or extent of sleep; a readily reversible state of reduced awareness and metabolic activity that occurs periodically in many animals. |
| | GO:0042493 | | response to drug | | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a drug stimulus. A drug is a substance used in the diagnosis, treatment or prevention of a disease. |
| | GO:0042542 | | response to hydrogen peroxide | | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a hydrogen peroxide (H2O2) stimulus. |
| | GO:0001666 | | response to hypoxia | | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating lowered oxygen tension. Hypoxia, defined as a decline in O2 levels below normoxic levels of 20.8 - 20.95%, results in metabolic adaptation at both the cellular and organismal level. |
| | GO:0043278 | | response to morphine | | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a morphine stimulus. Morphine is an opioid alkaloid, isolated from opium, with a complex ring structure. |
| | GO:0033197 | | response to vitamin E | | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a vitamin E stimulus. |
| | GO:0001829 | | trophectodermal cell differentiation | | The process in which a relatively unspecialized cell acquires the specialized features of a trophectoderm cell. |
| | GO:0046111 | | xanthine biosynthetic process | | The chemical reactions and pathways resulting in the formation of xanthine, 2,6-dihydroxypurine, a purine formed in the metabolic breakdown of guanine but not present in nucleic acids. |
| cellular component |
|---|
| | GO:0030054 | | cell junction | | A cellular component that forms a specialized region of connection between two or more cells or between a cell and the extracellular matrix. At a cell junction, anchoring proteins extend through the plasma membrane to link cytoskeletal proteins in one cell to cytoskeletal proteins in neighboring cells or to proteins in the extracellular matrix. |
| | GO:0009986 | | cell surface | | The external part of the cell wall and/or plasma membrane. |
| | GO:0005737 | | cytoplasm | | All of the contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures. |
| | GO:0031410 | | cytoplasmic vesicle | | A vesicle found in the cytoplasm of a cell. |
| | GO:0060205 | | cytoplasmic vesicle lumen | | The volume enclosed by a cytoplasmic vesicle. |
| | GO:0005829 | | cytosol | | The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes. |
| | GO:0032839 | | dendrite cytoplasm | | All of the contents of a dendrite, excluding the surrounding plasma membrane. |
| | GO:0009897 | | external side of plasma membrane | | The leaflet of the plasma membrane that faces away from the cytoplasm and any proteins embedded or anchored in it or attached to its surface. |
| | GO:0005615 | | extracellular space | | That part of a multicellular organism outside the cells proper, usually taken to be outside the plasma membranes, and occupied by fluid. |
| | GO:0005764 | | lysosome | | A small lytic vacuole that has cell cycle-independent morphology and is found in most animal cells and that contains a variety of hydrolases, most of which have their maximal activities in the pH range 5-6. The contained enzymes display latency if properly isolated. About 40 different lysosomal hydrolases are known and lysosomes have a great variety of morphologies and functions. |
| | GO:0016020 | | membrane | | A lipid bilayer along with all the proteins and protein complexes embedded in it an attached to it. |
| | GO:0043025 | | neuronal cell body | | The portion of a neuron that includes the nucleus, but excludes cell projections such as axons and dendrites. |
| | GO:0005886 | | plasma membrane | | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. |
Description
